🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. Ontruzant 420 mg powder for concentrate for solution for infusion, Oxaliplatin onkovis 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    HER2-positive, localized esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  2. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  3. Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, 5-FU medac 50 mg/ml, Injektionslösung, DS-8201a

    The George Institute

    HER2 positive resectable esophagogastric adenocarcinoma

    phase 2 small molecule active

    1 trial

  4. PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , Lenvatinib, BEVACIZUMAB , CAPECITABINE , CARBOPLATIN , FLUOROURACIL , OXALIPLATIN , GEMCITABINE , CISPLATIN , MK-7684A, Lenvatinib

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  5. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  6. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  7. PACLITAXEL ALBUMIN-BOUND, PACLITAXEL , DOCETAXEL , Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion., mRNA-4157, CARBOPLATIN

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  8. PACLITAXEL, LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  10. PARACETAMOL , FEXOFENADINE , CETIRIZINE , DEXAMETHASONE , mRNA-3745, DIPHENHYDRAMINE , CARBOHYDRATES , IBUPROFEN , HYDROXYZINE , FAMOTIDINE , Isotonische Kochsalzlösung Fresenius, Infusionslösung, ONDANSETRON

    Moderna Biotech Spain

    Glycogen storage disease type 1a (GSD1a)

    phase 2 small molecule active

    1 trial

  11. PEMETREXED DISODIUM, PACLITAXEL, CARBOPLATIN, CISPLATIN, PACLITAXEL ALBUMIN-BOUND, Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. PEMETREXED, Tusamitamab ravtansine, CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  13. PF-08634404, YERVOY 5 mg/ml concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  14. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 2 small molecule active

    1 trial

  15. PONATINIB, CYCLOPHOSPHAMIDE, VINCRISTINE, BESPONSA 1 mg powder for concentrate for solution for infusion, METHOTREXATE, PURINETHOL 50 mg compresse, PREDNISONE

    Fondazione Telethon ETS

    Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients

    phase 2 small molecule active

    1 trial

  16. POTELIGEO 4 mg/mL concentrate for solution for infusion

    KYOWA KIRIN AUSTRALIA PTY LTD

    Mycosis fungoides/Sezary syndrome recurrent

    phase 2 small molecule active

    1 trial

  17. PREDNISOLONE , MabThera 100 mg concentrate for solution for infusion, PREDNISONE , MabThera 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Minimal Change Nephrotic Syndrom

    phase 2 small molecule active

    1 trial

  18. PROLEUKIN® 18 x 106 IU Powder for solution for injection or infusion, Lifileucel, Cyclophosphamide Injection 1 g, FLUDARABINE

    Iovance Biotherapeutics B.V.

    Previously treated advanced melanoma

    phase 2 small molecule active

    1 trial

  19. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Tislelizumab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  20. Paclitaxel Kabi 6 mg/ml koncentrátum oldatos infúzióhoz, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution à diluer pour perfusion, 68Ga-FAPI-46, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion, Epirubicin Eugia 2 mg/ml oplossing voor injectie, Cyclophosphamid beta 500 mg/ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  21. Padcev 30 mg powder for concentrate for solution for infusion, Bavencio 20 mg/mL concentrate for solution for infusion

    The George Institute

    locally advanced or metastatic penile squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  22. Padcev 30 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Padcev 20 mg powder for concentrate for solution for infusion

    Disc Medicine

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  23. Pembrolizumab 200 mg IV infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IIIB(N2) Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  24. Pemetrexed EVER Pharma 25 mg/ml concentrate for solution for infusion, BI 1810631, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion.

    Boehringer Ingelheim

    locally advanced or metastatic NSCLC

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources